Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorogenic acid in preparation of medicines for treating cardiomyopathy

A kind of cardiomyopathy, chlorogenic acid technology, applied in the field of medicine, to achieve the effect of benefiting recovery, improving shape and inhibiting apoptosis

Inactive Publication Date: 2015-05-27
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the research on chlorogenic acid in the treatment of cardiomyopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparation of medicines for treating cardiomyopathy
  • Application of chlorogenic acid in preparation of medicines for treating cardiomyopathy
  • Application of chlorogenic acid in preparation of medicines for treating cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0022] Example 1: In vivo pharmacodynamics study on the treatment of dilated cardiomyopathy (DCM) with chlorogenic acid

[0023] 1. Experimental materials

[0024] 1.1 Animals

[0025] There are 110 Wistar rats born two weeks old and breast-fed, half male and half male.

[0026] 1.2 Experimental Drugs and Instruments

[0027] Furazolidone, 10% chloral hydrate, PHLIPsonos7500 color ultrasonic detector, TUNEL apoptosis detection kit, BNP ELISA detection kit, 1 / 10,000 electronic balance, disodium edetate.

[0028] 2. Experimental method

[0029] 2.1 Establishment of rat dilated cardiomyopathy (DCM) model and experimental grouping

[0030] Take 115 2-week-old Wistar rats, half male and half male, and randomly select 12 rats as the normal control group of the experiment, and feed them with normal rat diet. At the same time, the remaining 103 rats were used as model rats and started to be fed with furazolidone. Rats were fed for 8 weeks.

[0031] After 8 weeks, the dead 4 rat...

example 2

[0063] Example 2: The effect of chlorogenic acid on the expression of ACTC1, caspase-3, Bcl-2 genes and their respective corresponding proteins in cardiomyocytes of dilated cardiomyopathy rat model.

[0064] 1. Experimental materials

[0065] 1.1 Animals

[0066] There are 80 Wistar rats born two weeks old and breast-fed, half male and half male.

[0067] 1.2 Experimental Drugs and Instruments

[0068] Furazolidone, 10% chloral hydrate, PHLIPsonos7500 color ultrasonic detector, PCR instrument, total RNA extraction kit, cDNA first strand synthesis kit, electrophoresis apparatus, gel imager.

[0069] 2. Experimental method

[0070] 2.1 Establishment of rat dilated cardiomyopathy (DCM) model and experimental grouping

[0071] Take 60 2-week-old Wistar rats, half male and half male, randomly select 10 rats as the normal control group of the experiment, and feed them with normal rat diet. At the same time, the remaining 50 rats were used as model rats, and began to be fed with...

Embodiment 3

[0115] Example 3 In vivo pharmacodynamics study on the therapeutic effect of chlorogenic acid on hypertrophic cardiomyopathy

[0116] 1. Experimental materials

[0117] 1.1 Animals

[0118] cT R92Q Transgenic hypertrophic cardiomyopathy (HCM) model C57BL / 6J mice

[0119] 1.2 Experimental Drugs and Instruments

[0120] 10% chloral hydrate, PHLIPsonos7500 color ultrasonic detector, one ten-thousandth electronic balance, high power microscope.

[0121] 2. Experimental method

[0122] 2.1 Grouping of mice

[0123] cTnT R92Q Thirty-two transgenic hypertrophic cardiomyopathy model C57BL / 6J mice were randomly divided into 4 groups with 8 mice in each group. They were respectively set as the model control group (HCM group, n=8), the Metoprolol treatment group (Metoprolol group, n=8), and the chlorogenic acid treatment group (L-LYS group, n=8). At the same time, 8 wild-type C57BL / 6J mice were used as the normal control group (NC group, n=8) for the experiment.

[0124] 2.2 Exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of chlorogenic acid in preparation of medicines for treating cardiomyopathy. The medicines have the effects of up-regulating myocardial specific expression structure genes ACTC1 and corresponding protein, down-regulating caspase-3 genes and corresponding protein thereof, and up-regulating Bc1-2 genes and corresponding protein. The invention also discloses a medicine for treating cardiomyopathy, and the medicine comprises chlorogenic acid and pharmaceutically acceptable auxiliary materials or auxiliary components. The invention also discloses a combined medicine for treating cardiomyopathy.

Description

technical field [0001] The invention relates to the use of chlorogenic acid in the preparation of medicines for treating cardiomyopathy, and belongs to the field of medicines. Background technique [0002] Chlorogenic acid (CGA), also known as coffee tannin, is a depsipolic acid composed of caffeic acid CA and quinic acid QA, and its chemical name is 3-o-caffeoylquini acid (3-o-caffeoylquinic acid CGA). Chlorogenic acid is a phenylpropanoid synthesized by plants through the intermediate product of the pentose phosphate pathway during the process of aerobic respiration. Chlorogenic acid has been widely used in many fields such as food, health care products, cosmetics and pharmaceuticals. Because it widely exists in various common vegetables and fruits, it has a variety of biological activities, such as: cardiovascular protection, anti-oxidation, anti-ultraviolet and anti-radiation effects, anti-mutagenesis and anti-cancer effects, antibacterial effects, anti-inflammatory ef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/277A61K31/554A61P9/00A61P9/04A61K31/138A61K31/165
CPCA61K31/138A61K31/165A61K31/216A61K31/277A61K31/554
Inventor 张洁张梦甜黄望
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com